Xylem Inc.
XYL
$105.69
-2.04%
Xylem Inc. is a global water technology company that provides solutions for water transport, treatment, testing, and efficient use across utility, industrial, commercial, and residential sectors. As a market leader spun off from ITT in 2011, Xylem differentiates itself through its comprehensive portfolio and focus on sustainability, serving customers in over 150 countries. The current investor narrative centers on the company's growth trajectory amid global water scarcity and infrastructure investment, but recent stock performance has been pressured by broader market volatility and concerns about end-market demand. Xylem's strategic initiatives, including digital transformation and acquisitions, are key points of debate as investors weigh its long-term potential against near-term headwinds.…
XYL
Xylem Inc.
$105.69
Investment Opinion: Should I buy XYL Today?
Rating: Buy. The stock is trading at $105.69, with an average analyst target of $153.875, implying 45.6% upside. The consensus recommendation is Buy, and the forward PE of 16.9x is attractive relative to the expected EPS growth. The thesis is that the market has overreacted to near-term growth deceleration, and the company's strong cash flow and strategic position in water technology will drive a recovery.
Sign up to view all
XYL 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stock's valuation on forward earnings is attractive, but the decelerating revenue growth and negative price momentum create uncertainty. The wide range of analyst targets (129-180) reflects high dispersion in expectations. If the company can stabilize growth and deliver on earnings estimates, the stock could recover significantly. However, if growth continues to slow, the stock may remain under pressure. Key factors to watch are Q2 2026 earnings and any changes to full-year guidance.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Xylem Inc.'s 12-month outlook, with a consensus price target around $153.88 and implied upside of +45.6% versus the current price.
Average Target
$153.88
0 analysts
Implied Upside
+45.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$129 - $180
Analyst target range
The target price range spans from a low of $129.00 to a high of $180.00, reflecting a wide dispersion of 39.5% between the lowest and highest estimates. The high target of $180 suggests that some analysts expect a strong recovery, possibly driven by accelerating infrastructure spending and successful execution of growth initiatives. The low target of $129 implies a more conservative outlook, factoring in potential margin pressure or slower demand. The wide range indicates high uncertainty about Xylem's near-term prospects, but the average target still points to significant upside, suggesting that analysts believe the current sell-off is overdone.
Bulls vs Bears: XYL Investment Factors
The bearish case currently holds stronger evidence, as the stock's technical downtrend, decelerating revenue growth, and premium valuation present significant near-term risks. However, the bullish case is supported by a low forward PE, strong free cash flow, and a consensus Buy rating with substantial upside to analyst targets. The central tension is whether the market's pessimistic outlook is justified by slowing growth or whether the stock is oversold given its long-term secular demand drivers. If revenue growth reaccelerates or the company delivers on earnings expectations, the stock could rebound sharply; otherwise, it may continue to drift lower.
Bullish
- Forward PE at 16.9x signals earnings growth: The trailing PE of 34.65x versus forward PE of 16.92x implies the market expects a substantial earnings increase, likely from cost synergies and operational improvements. This gap suggests analysts see EPS growing to $7.78 (estimated average) from current levels, making the stock look attractively priced on forward earnings.
- Strong free cash flow generation: Xylem generated $966 million in free cash flow over the trailing twelve months, providing ample capacity for dividends, debt reduction, and strategic acquisitions. This cash generation supports the company's ability to invest in growth initiatives and return capital to shareholders.
- Healthy balance sheet with low leverage: With a debt-to-equity ratio of only 0.18 and a current ratio of 1.625, Xylem maintains a conservative capital structure. This financial flexibility allows the company to weather economic downturns and pursue opportunistic M&A without straining its balance sheet.
- Analyst consensus is Buy with 45.6% upside: The average analyst target price of $153.875 represents a 45.6% upside from the current price of $105.69, with a low target of $129 still implying 22% upside. The consensus recommendation is 'Buy' (mean score 1.86), indicating that sell-side analysts view the recent sell-off as overdone.
Bearish
- Revenue growth decelerating sharply: Q1 2026 revenue grew only 2.7% YoY, down from 8.5% in Q4 2025, indicating a clear slowdown. This deceleration suggests weakening demand across key end markets, which could pressure future earnings and justify the stock's decline.
- Stock in a steep downtrend near 52-week low: The stock is trading at $105.69, just 0.4% above its 52-week low of $105.29, and has fallen 25.5% over the past year. The persistent selling pressure and inability to hold rallies reflect a lack of buyer conviction and negative market sentiment.
- Premium valuation to sector on sales: The PS ratio of 3.67x is 23% above the industry average of 2.98x (EV/Sales), indicating investors are paying a premium for Xylem's revenue. If growth continues to slow, this premium could compress, leading to further downside.
- High PEG ratio suggests overvaluation: The PEG ratio of 4.89x is elevated, implying that the stock's growth prospects do not justify its current valuation. This metric suggests that the market is pricing in optimistic earnings growth that may not materialize, making the stock vulnerable to de-rating.
XYL Technical Analysis
Xylem's stock is in a pronounced downtrend, with the price at $105.69 as of September 4, 2026, reflecting a 25.5% decline over the past year. The stock is trading near its 52-week low of $105.29, just 0.4% above that level, and significantly below its 52-week high of $154.27, indicating it is at the bottom of its 52-week range. This positioning suggests a potential value opportunity, but also signals persistent selling pressure and a lack of buyer conviction, as the stock has been unable to hold onto any rallies.
Beta
1.00
1.00x market volatility
Max Drawdown
-30.9%
Largest decline past year
52-Week Range
$105-$154
Price range past year
Annual Return
-25.5%
Cumulative gain past year
| Period | XYL Return | S&P 500 |
|---|---|---|
| 1m | -13.5% | -0.4% |
| 3m | -3.9% | +4.2% |
| 6m | -14.2% | +13.7% |
| 1y | -25.5% | +19.0% |
| ytd | -22.9% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
XYL Fundamental Analysis
Xylem's revenue growth has decelerated, with the most recent quarter (Q1 2026) showing revenue of $2.125 billion, a 2.7% year-over-year increase, down from the 8.5% growth seen in Q4 2025. The company's revenue segments show Water Infrastructure as the largest at $2.055 billion, followed by Measurement and Control Solutions at $1.596 billion and Applied Water at $1.414 billion, but growth is slowing across the board. This deceleration suggests that the company is facing demand headwinds, possibly due to macroeconomic uncertainty and project delays, which could pressure future revenue growth.
Quarterly Revenue
$2.1B
2026-03
Revenue YoY Growth
+2.7%
YoY Comparison
Gross Margin
37.8%
Latest Quarter
Free Cash Flow
$966000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is XYL Overvalued?
Given Xylem's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 34.65x, while the forward PE is 16.92x, indicating that the market expects significant earnings growth in the next year, as the forward multiple is much lower. This gap suggests that analysts anticipate a substantial increase in earnings, possibly due to cost synergies from recent acquisitions or operational improvements. The stock is trading at a premium to the sector, with a PS ratio of 3.67x compared to the industry average of 2.98x (EV/Sales), implying investors are paying a 23% premium for Xylem's revenue, which may be justified by its market leadership and stable margins.
PE
34.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 22x~63x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Xylem faces risks from decelerating revenue growth, which fell to 2.7% YoY in Q1 2026 from 8.5% in Q4 2025, potentially indicating weakening demand. The company's net margin of 10.6% and operating margin of 13.5% are respectable but could compress if input costs rise or pricing power diminishes. With a debt-to-equity ratio of 0.18, leverage is low, but the company's reliance on continued growth to justify its forward PE of 16.9x means any earnings miss could trigger a de-rating. Free cash flow of $966 million provides a cushion, but if cash conversion deteriorates, dividend sustainability (payout ratio 40.9%) could be questioned.